Skip to main content

Table 2 Serum and BALF MMP concentrations

From: Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis

 

IPF

COPD

Control

p-value

p-value

p-value

(n = 57)

(n = 20)

(n = 15)

IPF vs. Control

IPF vs. COPD

COPD vs. Control

Serum

      

MMP-1, ng/mL

1.52 ± 1.36

0.95 ± 0.74

0.60 ± 0.58

0.005

NS

NS

MMP-2, ng/mL

73.5 ± 60.8

27.6 ± 11.8

41.3 ± 40.6

0.034

<0.001

NS

MMP-3, ng/mL

8.43 ± 10.51

4.54 ± 2.26

3.78 ± 3.00

NS

NS

NS

MMP-7, ng/mL

8.39 ± 4.32

1.72 ± 0.65

2.14 ± 1.41

<0.001

<0.001

NS

MMP-8, ng/mL

1.43 ± 1.50

0.80 ± 0.62

0.47 ± 0.51

0.012

NS

NS

MMP-9, ng/mL

38.7 ± 26.8

23.3 ± 15.7

25.9 ± 24.0

NS

0.030

NS

MMP-10, ng/mL

1.18 ± 0.83

0.16 ± 0.18

0.18 ± 0.18

<0.001

<0.001

NS

MMP-12, ng/mL

0.31 ± 0.23

0.17 ± 0.11

<0.1a

<0.001

0.013

<0.001

MMP-13, ng/mL

<0.1a

<0.1a

<0.1a

   

KL-6, U/mL

1084.2 ± 724.4

   

SP-D, ng/mL

300.4 ± 223.7

   

BALF

      

MMP-7, ng/mL

9.6 ± 10.7

   

MMP-10, ng/mL

0.10 ± 0.09

   
  1. The data are presented as the mean ± standard deviation
  2. IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, MMP matrix metalloproteinase, NS not significant, KL-6 Krebs von den lungen-6, SP-D surfactant protein-D, BALF bronchoalveolar lavage fluid
  3. aThe mean is under the limit of determination